药学毕业万拉法新与西酞普兰治疗抑郁症对照研究.docxVIP

XX大学 毕业论文 万拉法新与西瞅普兰治疗抑郁症对照研究 2014年6月25日 作者：杨忠宋静波尹建兵谭文钟 【关键词】 万拉法新；西猷普兰；抑郁症；汉密顿抑郁量表；副反应量表 【摘要】目的评价万拉法新与西瞅普兰治疗抑郁症的临床疗效及安全 性。方法 将65例抑郁症患者随机分为万拉法新组32例，西瞅普兰组33例， 观察6wo于治疗前和治疗lw、2w、6 w末采用汉密顿抑郁量表评定疗效，副 反应量表评定不良反应。结果万拉法新组显效率80.6%,西猷:普兰组77.4%, 两组比较差异无显著性(P0.05)；治疗第lw末万拉法新组汉密顿抑郁量表评 分显著低于西駄普兰组(P0.05)。2w、4w、6 w末两组评分比较差异无显著 性(P0.05)；万拉法新组不良反应发生率46.9%,西瞅普兰组39.4%,两组比 较差异无显著性(P0.05)o结论 万拉法新与西駄普兰治疗抑郁症具有同等 疗效，但万拉发新起效较西猷;普兰快。 【关键词】万拉法新；西瞅普兰；抑郁症；汉密顿抑郁量表；副反应量 表 A control study on venlafaxine vs. citaloparm in the treatment of depression [Abstract ] Objective To evaluate the clinical curative effects and safety of venlafaxine vs. citaloparm in the treatment of depression. Methods 65 patients with depressive disorder were randomly divided into venlafaxine(n=32) and citaloparm(n=33) group for 6 weeks. The curative effects were assessed with the Hamilton Depression Scale (HAMD) and adverse effects with the Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of the 1st, 2nd and 6th week, respectively. Results Excellence rates were respectively 80.6% in venlafaxine and 77.4% in the citalopann group, which showed no significant difference(P0.05); at the end of the 1st week, score of the HAMD was significantly lower in the venlafaxine than in the citaloparm group(P0.05). There were no significant differences at the ends of the 2nd, 4th and 6th week between the 2 groups(P0.05); incidences of adverse effects were respectively 46.9% in the venlafaxine and 39.4% in the citaloparm group, difference was not significant(P0.05). Conclusion Venlafaxine has therapeutic equivalence to citaloparm in depression, but takes efleets faster. 【Keywords 】 Venlafaxine; citaloparm; depression; the HAMD; the TESS 有文献表明[1], 30%的抑郁症患者对各种治疗没有反应，40%?45%的 慢性抑郁症患者缺乏治疗反应。且在临床治疗过程中发现，不同的药物有着不尽 相同的副作用。为此作者采用万拉法新(商品名：怡诺思)与西猷普兰(商品名: 喜普妙)进行了对照研究，以探讨万拉法新的临床疗效及安全性，现报告如下。 1对象与方法 1」对象 选取2005年5月~2006年5月在我院门诊及住院治疗的65例 抑郁症患者为研究对象。入组标准：(1)符合《屮国精神障碍分类与诊断标准》 第3版(CCMD3)抑郁症诊断标准；(2)年龄24a?81 a； (3)汉密顿抑郁量表 (HAMD)评分218分；(4